overal in-lin organ revenu growth similar last
quarter put take segment perform remain
consist diabet diagnost outperform neuromod
establish pharma surprisingli weak high level management
address consensu estim suggest comfort
ep growth rang despit fx variabl less
enthusiasm current avail asset feel cash like use
nt repay debt potenti increas dividend even without tuck-
in feel deliv organ revenue growth upcom catalyst
mitraclip fmr alin diabet momentum etc overal
view unchang slightli trim estim adjust
currenc model line view
valuat ntm ep appropri maintain neutral rate
feel hit cylind current reflect
littl surpris segment revenu standout includ
ou diabet result driven libr momentum better diagnost
result thank alin eu vascular upsid sierra ramp
flip side neuromod result continu lag due salesforc
chang establish pharma fell bit short expect overal
china growth rate remain strong management say end-
market seem stabl management reiter view impact
announc tariff would limit ep
strong quarter compani estim
world-wide user libr believ new
cgm user ad convert mean
dxcm result strong quarter well seem
commit lower price open larg market
think must match price
valuat maintain neutral rate risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
report revenu forecast
medic devic segment drove greatest upsid vs model strength
seen ww diabet structur heart
diabet revenu continu momentum libr
sale structur heart saw growth mitraclip double-digit
growth amplatz pfo neuromod result weaker
expect due linger issu salesforc front manag
expect quarter lag result
turn diagnost segment sale grew alin growth continu
stellar europ placement share captur
establish pharma came lower estim hurt tough y/i
comparison channel restock india last year even russia
lastli nutrit result back strong perform ou
ensur glucerna continu trend well intern
gross margin ahead estim note underli
gm ex-curr up-tick oper expens in-lin
higher sg off-set lower line expens
interest came model tax rate in-lin net-net adj ep
penni forecast in-lin consensu
actualsbtig estimate variancetot incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
make number chang estim revenu flow
upsid rais estim structur heart diabet
diagnost trim ou neuromod ep estim final
forecast sizeabl fx headwind origin model
recalcul currenc model
tweak gross margin forecast base ytd trend
rais ebit margin estim slightli
keep adj ep estim unchang fx risk
trim adj ep growth
abbott rate neutral share appreci remark
year strong product launch remain posit abt base busi
see pathway drive mid-to-high singl digit growth
although mitraclip still modest portion busi expect
signific ramp label expans said share trade
premium comp group feel share rel valuat
appropri reflect risk vs reward btig provid price target
neutral-r stock risk rate includ multipl expans
fall favor fda regulatori agenc product delay failur
execut merger synergi
net ep gross bpsadj ebit bpssourc btig estim compani filingsnewold chang
exhibit comp tabl large-cap peer
cagrntm johnsonjnjund fishertmobuy bdxnot scientificbsxbuy factset data btig estimatesintra-day price ex-amortcompanytickerr ptpricemarket cap bev/sal
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growthy/i growth oper adj aleretot y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
btig cover compani mention report
appendix analyst certif import disclosur
